Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A. Imel, Anthony A. Portale, Noriyuki Namba et al.|The Lancet|2019Cited by 375
Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trialMichael P. Whyte, Erik A. Imel, Thomas O. Carpenter et al.|The Lancet Diabetes & Endocrinology|2019Cited by 184
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M. Ward, Erik A. Imel, Francis H. Glorieux et al.|The Journal of Clinical Endocrinology & Metabolism|2022Cited by 78
KRN23 effects on phosphate and vitamin D dysregulation in children <5 years old with X-Linked Hypophosphatemia (XLH)Erik A. Imel, Michael P. Whyte, Thomas Carpenter et al.|Bone Abstracts|2017Cited by 2